Naim Mohammed, Kumar Amit, Gaur Kavita, John Vanesa T
Pathology Department, JNMC AMU Aligarh, Aligarh, Uttar Pradesh, India.
BMJ Case Rep. 2010 Nov 23;2010:bcr0520103008. doi: 10.1136/bcr.05.2010.3008.
Oestrogen-progestrone-Her2neu receptor status was studied in various loci/foci of heterogeneous carcinoma of the breast and its metastatic secretory component in the lymph node in a lactating woman. All the carcinoma variants were negative for the trio markers except tumour components evolved to secretory or lactating carcinoma, which showed focal positivity. Findings showed that oestrogenic receptors, progesterone receptors and Her2neu negative primitive carcinoma in a heterogenous breast cancer may evolve into oestrogen receptor, progesterone receptor and Her2neu positive secretory/lactating carcinoma alongside other receptor negative carcinoma variants. Focal marker positivity/negativity underlined the fact that a diagnostic/prognostic marker status report may account for the tumour area included in the section/sample only. Study of the immune marker expression/status in various loci may help identification of the components, morphogenesis and dynamics of heterogeneous carcinoma of the breast.
在一名哺乳期妇女的乳腺异质性癌及其淋巴结转移分泌成分的不同位点/病灶中,研究了雌激素-孕激素-Her2neu受体状态。除演变为分泌性或泌乳性癌的肿瘤成分呈局灶性阳性外,所有癌变体的这三种标志物均为阴性。研究结果表明,异质性乳腺癌中雌激素受体、孕激素受体和Her2neu阴性的原始癌可能会演变为雌激素受体、孕激素受体和Her2neu阳性的分泌性/泌乳性癌,同时伴有其他受体阴性的癌变体。局灶性标志物阳性/阴性突出了这样一个事实,即诊断/预后标志物状态报告可能仅反映切片/样本中包含的肿瘤区域。对不同位点免疫标志物表达/状态的研究可能有助于识别乳腺异质性癌的成分、形态发生和动态变化。